Our Leadership
Building on
a History of Success
Our Leadership
Building on
a History of Success
Our Leadership
Building on a History of Success
Millicent was founded in 2018 by pharmaceutical industry veterans—
Roger Boissonneault, Dr. John King, and Geoffrey Elliott—along with
The Carlyle Group and Bourne Partners.
Millicent was founded in 2018 by pharmaceutical industry veterans—Roger Boissonneault, Dr. John King, and Geoffrey Elliott—along with The Carlyle Group and Bourne Partners.
In the years since, Millicent has cultivated a Senior Leadership Team comprised of consummate professionals who bring a breadth of experience in the development, acquisition, and commercialization of pharmaceuticals focused on improving women’s health.
In the years since, Millicent has cultivated a Senior Leadership Team
comprised of consummate professionals who bring a breadth of experience
in the development, acquisition, and commercialization
of pharmaceuticals focused on improving women’s health.
Roger Boissonneault
Chief Executive Officer
Roger was one of the original founders of Millicent and is a successful CEO with
sustained long-term success in managing multibillion dollar pharmaceutical
companies to significant increases of scale and earnings. He has industry-leading
expertise in women’s health and gastroenterology. Over the course of 15 years,
Roger transformed Warner Chilcott’s 30-person generics platform of $65 million
into a multibillion dollar corporation focused on the women’s health,
gastroenterology, urology, and dermatology franchises.
Roger has significant knowledge in all areas of capital deployment with execution
in the mergers and acquisitions, debt, and equity markets. A visionary innovator,
he holds 15 patents, along with multiple pending applications that have been
oundational for numerous market-leading franchises.
Roger has a Bachelor of Science degree in Biology from the University of
Connecticut and a Master of Business Administration from Rutgers University.
Andy McClenaghan
President
Andy is an accomplished leader with more than 30 years of broad operational
experience in pharmaceuticals. He has resolved the toughest challenges faced
in developing and commercializing pharmaceuticals and building winning brands
that achieve category leadership. Prior to helping found Millicent, he started a
new commercial division at Mayne Pharma, served as Head of Commercial
Operations at Warner Chilcott launching multiple key new products, and was
General Manager of Procter & Gamble Pharma in Canada.
Andy has a Bachelor of Chemical Engineering and Management degree from
McMaster University.
Greg Ourednik
Executive Vice President, Commercial Operations
Greg brings more than 25 years of leadership experience in the healthcare industry,
with a proven history of driving operational excellence and strategic growth across
leading global organizations. Prior to joining Millicent, Greg served as General
Manager and Executive Director at Quest Diagnostics, the world’s leading provider
of diagnostic information services. He previously held senior leadership roles at
Warner Chilcott, where he served as Head of Global Supply and Senior Director
of Business Operations. Earlier in his career, Greg spent more than a decade at
Procter & Gamble, where he held a series of increasingly senior roles in
healthcare and operations.
Greg has a Bachelor of Science degree in Chemical Engineering from the
University of Notre Dame.
Ryan Loughlin
Senior Vice President, Head of Technical Operations and Quality
Ryan leads Millicent’s technical operations, which includes R&D, operational
excellence, and product validations. He is also responsible for Millicent Quality,
with quality oversight for R&D, clinical, manufacturing, and distribution.
Ryan has 18 years of experience in R&D, operational excellence, manufacturing,
and quality-related functions. He joined Millicent as Vice President, Head of
Pharmaceutical Development & Pharmaceutical Technology. Prior to this role,
Ryan held various senior positions at Adapt Pharma, Allergan, and Warner Chilcott.
Ryan has a Master’s degree in Pharmacy and a PhD in Pharmaceutics from
Queen’s University Belfast.
Anne Marie Tipa
Vice President, Sales and Marketing
Anne Marie has more than 20 years of experience in pharmaceutical sales
leadership, training, and marketing, including various product launches. She
joined Millicent shortly after its founding to develop and expand the Women’s
Healthcare Sales and Marketing teams. Anne Marie led the sales and
marketing strategy for all the products in the portfolio and recently launched
Femlyv, the first New Drug Application (NDA) developed, approved, and
launched for Millicent. Before joining Millicent, she created and launched the
first specialty brand team at Mayne Pharma and was a driving force in the
commercial development of its first hospital division. Prior to Mayne Pharma,
Anne Marie successfully delivered in roles of increasing scope and
responsibility within sales leadership, marketing, and training functions
at Warner Chilcott.
Anne Marie has a Bachelor of Arts degree in Business Administration from
the University of Mary Washington.
Ilka Schellschmidt
Vice President, Clinical and Medical Affairs
Ilka has more than 25 years of experience in clinical research and development. She
joined Millicent to lead Clinical and Medical Affairs from Organon, where she was
Vice President, Head of Global Clinical Development. In that role, she oversaw the
clinical development activities, operational execution, and clinical assessment of
in-licensing opportunities, with a strong focus on Women's Health. Prior to Organon,
she worked as Head of the Therapeutic Area Women's Health at Bayer, responsible
for strategy, external opportunities, and execution in Clinical Development and
Project Management.
Ilka has a Medical degree from the Free University of Berlin and is a board-certified
Clinical Pharmacologist.
Francisco (Frank) Rodriguez
President, Millicent Puerto Rico
Frank is a seasoned executive with more than 30 years of experience in
pharmaceutical manufacturing, engineering, and operational leadership.
He has held key roles at major global pharmaceutical companies, including
Warner Chilcott, Actavis, Teva, Cephalon, Mylan, and Schering-Plough,
overseeing strategic operations, facility expansions, compliance initiatives,
and manufacturing transitions. His expertise and leadership have been
instrumental in optimizing manufacturing efficiency, logistics, and
organizational transitions and development. Frank's leadership has been
recognized with industry accolades, including the Industrial Person of the
Year award from the Puerto Rico Manufacturers Association.
Frank has a Bachelor of Science degree in Chemical Engineering from
Manhattan University.
Claire Gilligan
Vice President, Scientific Affairs
Claire has more than 30 years of leadership experience in pharma, primarily
overseeing Quality and R&D. Prior to joining Millicent, Claire helped establish
Theramex as a newly formed pharmaceutical company. Before Theramex,
she was Senior Vice President of Global Quality for Allergan, leading the
Quality organization across 40 manufacturing sites and 18 countries. Prior
to Allergan, Claire worked at Warner Chilcott for more than 20 years in roles
of increasing responsibility, including Vice President of Pharmaceutical
Development and Senior Vice President of Quality.
Claire has a Bachelor of Science degree in Pharmacy from the University
of Strathclyde and a PhD in Pharmaceutics from Queen’s University Belfast.
Alvin Howard
Vice President, Regulatory
Alvin brings more than 40 years of experience in the pharmaceutical industry,
with a broad and deep background in regulatory affairs, compliance, and quality
assurance/control. Throughout his career, Alvin has played a key role in the
successful approval of more than 15 New Drug Applications (NDAs) and has
led regulatory and quality initiatives across U.S. and European operations. He has
a strong record of collaborating with global regulatory authorities to advance
development programs, ensuring compliance and facilitating market approvals.
Before joining Millicent, Alvin served as Vice President of Regulatory Affairs at
Foamix Pharmaceuticals. His prior roles include Senior Vice President and Head
of Regulatory Affairs at Warner Chilcott, and Vice President of Regulatory Affairs
at Roberts Pharmaceuticals.
Alvin has a Bachelor of Science degree in Chemistry from Stillman College.
Ali Mustafa
Vice President, Finance
Ali joined Millicent with more than 15 years of finance/accounting experience across
the pharmaceutical, medtech, and manufacturing sectors. Prior to joining Millicent,
Ali worked at ConvaTec in roles of increasing responsibilities and scope as Finance
lead for the U.S. Ostomy team, the Americas team, and Global Ostomy team. Ali
led the finance function supporting Sales and Marketing, Quality, and Product
Development at Catalent Pharma Solutions. He was also the Product Finance lead
for the Faucets and Luxury divisions at American Standard and Accounting/Financial
Planning & Analysis (FP&A) lead for the Corporate Finance team at Warner Chilcott.
Ali has a Bachelor of Science degree in Business Administration, with a concentration
in Accounting from Montclair State University.
Steve Celestini
Compliance Officer
Steve joined Millicent as its U.S. Compliance Officer. Steve has more than 30 years
of experience advising on regulatory compliance matters for global and U.S.
pharmaceutical companies (GSK, Salix, Inspire, and Mayne) in dozens of therapeutic
areas, including as In-house Legal Counsel, General Counsel, Chief Compliance
Officer, and Board Secretary.
Steve has a Bachelor of Arts degree in Political Science from Virginia Tech and a
Juris Doctor degree from Wake Forest University.
Roger Boissonneault
Chief Executive Officer
Roger was one of the original founders of Millicent and is a successful CEO with sustained long-term success in managing multibillion dollar pharmaceutical companies to significant increases of scale and earnings. He has industry-leading expertise in women’s health and gastroenterology. Over the course of 15 years, Roger transformed Warner Chilcott’s 30-person generics platform of $65 million into a multibillion dollar corporation focused on the women’s health, gastroenterology, urology, and dermatology franchises.
Roger has significant knowledge in all areas of capital deployment with execution in the mergers and acquisitions, debt, and equity markets. A visionary innovator, he holds 15 patents, along with multiple pending applications that have been foundational for numerous market-leading franchises.
Roger has a Bachelor of Science degree in Biology from the University of Connecticut and a Master of Business Administration from Rutgers University.
Andy McClenaghan
President
Andy is an accomplished leader with more than 30 years of broad operational experience in pharmaceuticals. He has resolved the toughest challenges faced in developing and commercializing pharmaceuticals and building winning brands that achieve category leadership. Prior to helping found Millicent, he started a new commercial division at Mayne Pharma, served as Head of Commercial Operations at Warner Chilcott launching multiple key new products, and was General Manager of Procter & Gamble Pharma in Canada.
Andy has a Bachelor of Chemical Engineering and Management degree from McMaster University.
Greg Ourednik
Executive Vice President, Commercial Operations
Greg brings more than 25 years of leadership experience in the healthcare industry, with a proven history of driving operational excellence and strategic growth across leading global organizations. Prior to joining Millicent, Greg served as General Manager and Executive Director at Quest Diagnostics, the world’s leading provider of diagnostic information services. He previously held senior leadership roles at Warner Chilcott, where he served as Head of Global Supply and Senior Director of Business Operations. Earlier in his career, Greg spent more than a decade at Procter & Gamble, where he held a series of increasingly senior roles in healthcare and operations.
Greg has a Bachelor of Science degree in Chemical Engineering from the University of Notre Dame.
Ryan Loughlin
Senior Vice President, Head of Technical Operations and Quality
Ryan leads Millicent’s technical operations, which includes R&D, operational excellence, and product validations. He is also responsible for Millicent Quality, with quality oversight for R&D, clinical, manufacturing, and distribution.
Ryan has 18 years of experience in R&D, operational excellence, manufacturing, and quality-related functions. He joined Millicent as Vice President, Head of Pharmaceutical Development & Pharmaceutical Technology. Prior to this role, Ryan held various senior positions at Adapt Pharma, Allergan, and Warner Chilcott.
Ryan has a Master’s degree in Pharmacy and a PhD in Pharmaceutics from Queen’s University Belfast.
Anne Marie Tipa
Vice President, Sales and Marketing
Anne Marie has more than 20 years of experience in pharmaceutical sales leadership, training, and marketing, including various product launches. She joined Millicent shortly after its founding to develop and expand the Women’s Healthcare Sales and Marketing teams. Anne Marie led the sales and marketing strategy for all the products in the portfolio and recently launched Femlyv, the first New Drug Application (NDA) developed, approved, and launched for Millicent. Before joining Millicent, she created and launched the first specialty brand team at Mayne Pharma and was a driving force in the commercial development of its first hospital division. Prior to Mayne Pharma, Anne Marie successfully delivered in roles of increasing scope and responsibility within sales leadership, marketing, and training functions at Warner Chilcott.
Anne Marie has a Bachelor of Arts degree in Business Administration from the University of Mary Washington.
Ilka Schellschmidt
Vice President, Clinical and Medical Affairs
Ilka has more than 25 years of experience in clinical research and development. She joined Millicent to lead Clinical and Medical Affairs from Organon, where she was Vice President, Head of Global Clinical Development. In that role, she oversaw the clinical development activities, operational execution, and clinical assessment of in-licensing opportunities, with a strong focus on Women's Health. Prior to Organon, she worked as Head of the Therapeutic Area Women's Health at Bayer, responsible for strategy, external opportunities, and execution in Clinical Development and Project Management.
Ilka has a Medical degree from the Free University of Berlin and is a board-certified Clinical Pharmacologist.
Francisco (Frank) Rodriguez
President, Millicent Puerto Rico
Frank is a seasoned executive with more than 30 years of experience in pharmaceutical manufacturing, engineering, and operational leadership. He has held key roles at major global pharmaceutical companies, including Warner Chilcott, Actavis, Teva, Cephalon, Mylan, and Schering-Plough, overseeing strategic operations, facility expansions, compliance initiatives, and manufacturing transitions. His expertise and leadership have been instrumental in optimizing manufacturing efficiency, logistics, and organizational transitions and development. Frank's leadership has been recognized with industry accolades, including the Industrial Person of the Year award from the Puerto Rico Manufacturers Association.
Frank has a Bachelor of Science degree in Chemical Engineering from Manhattan University.
Claire Gilligan
Vice President, Scientific Affairs
Claire has more than 30 years of leadership experience in pharma, primarily overseeing Quality and R&D. Prior to joining Millicent, Claire helped establish Theramex as a newly formed pharmaceutical company. Before Theramex, she was Senior Vice President of Global Quality for Allergan, leading the Quality organization across 40 manufacturing sites and 18 countries. Prior to Allergan, Claire worked at Warner Chilcott for more than 20 years in roles of increasing responsibility, including Vice President of Pharmaceutical Development and Senior Vice President of Quality.
Claire has a Bachelor of Science degree in Pharmacy from the University of Strathclyde and a PhD in Pharmaceutics from Queen’s University Belfast.
Alvin Howard
Vice President, Regulatory
Alvin brings more than 40 years of experience in the pharmaceutical industry, with a broad and deep background in regulatory affairs, compliance, and quality assurance/control. Throughout his career, Alvin has played a key role in the successful approval of more than 15 New Drug Applications (NDAs) and has led regulatory and quality initiatives across U.S. and European operations. He has a strong record of collaborating with global regulatory authorities to advance development programs, ensuring compliance and facilitating market approvals.
Before joining Millicent, Alvin served as Vice President of Regulatory Affairs at Foamix Pharmaceuticals. His prior roles include Senior Vice President and Head of Regulatory Affairs at Warner Chilcott, and Vice President of Regulatory Affairs at Roberts Pharmaceuticals.
Alvin has a Bachelor of Science degree in Chemistry from Stillman College.
Ali Mustafa
Vice President, Finance
Ali joined Millicent with more than 15 years of finance/accounting experience across the pharmaceutical, medtech, and manufacturing sectors. Prior to joining Millicent, Ali worked at ConvaTec in roles of increasing responsibilities and scope as Finance lead for the U.S. Ostomy team, the Americas team, and Global Ostomy team. Ali led the finance function supporting Sales and Marketing, Quality, and Product Development at Catalent Pharma Solutions. He was also the Product Finance lead for the Faucets and Luxury divisions at American Standard and Accounting/Financial Planning & Analysis (FP&A) lead for the Corporate Finance team at Warner Chilcott.
Ali has a Bachelor of Science degree in Business Administration, with a concentration in Accounting from Montclair State University.
Steve Celestini
Compliance Officer
Steve joined Millicent as its U.S. Compliance Officer. Steve has more than 30 years of experience advising on regulatory compliance matters for global and U.S. pharmaceutical companies (GSK, Salix, Inspire, and Mayne) in dozens of therapeutic areas, including as In-house Legal Counsel, General Counsel, Chief Compliance Officer, and Board Secretary.
Steve has a Bachelor of Arts degree in Political Science from Virginia Tech and a Juris Doctor degree from Wake Forest University.